SG-2501 is under clinical development by Hangzhou Sumgen Biotech and currently in Phase I for Relapsed Multiple Myeloma. According to GlobalData, Phase I drugs for Relapsed Multiple Myeloma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SG-2501’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hangzhou Sumgen Biotech overview
Hangzhou Sumgen Biotech formerly Hangzhou Shangjian Biotechnology Co Ltd is a drug developer, specializing in the development of therapeutic antibody drugs and the application of antibodies in immunotherapy and immunodiagnostics. Shangjian Biotechnology is headquartered in Hangzhou, Zhejiang, China.
For a complete picture of SG-2501’s drug-specific PTSR and LoA scores, buy the report here.